KR20160136465A - 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법 - Google Patents

수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법 Download PDF

Info

Publication number
KR20160136465A
KR20160136465A KR1020167032323A KR20167032323A KR20160136465A KR 20160136465 A KR20160136465 A KR 20160136465A KR 1020167032323 A KR1020167032323 A KR 1020167032323A KR 20167032323 A KR20167032323 A KR 20167032323A KR 20160136465 A KR20160136465 A KR 20160136465A
Authority
KR
South Korea
Prior art keywords
compound
sample
iic
melt
therapeutic compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020167032323A
Other languages
English (en)
Korean (ko)
Inventor
제임스 코왈스키
오스카 칼브
아부 티. 엠. 세라주딘
야틴드라 조시
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35447883&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20160136465(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20160136465A publication Critical patent/KR20160136465A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167032323A 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법 Withdrawn KR20160136465A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US60532704P 2004-08-27 2004-08-27
US60/605,327 2004-08-27
US61682804P 2004-10-07 2004-10-07
US60/616,828 2004-10-07
PCT/EP2005/009252 WO2006021455A1 (en) 2004-08-27 2005-08-26 Fast release composition including melt granules of a moisture sensitive drug and process for manufacturing thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167002363A Division KR20160017123A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177024422A Division KR20170103039A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법

Publications (1)

Publication Number Publication Date
KR20160136465A true KR20160136465A (ko) 2016-11-29

Family

ID=35447883

Family Applications (8)

Application Number Title Priority Date Filing Date
KR1020167032323A Withdrawn KR20160136465A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법
KR1020077004461A Ceased KR20070049646A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물및 그의 제조방법
KR1020137009959A Expired - Fee Related KR101613775B1 (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법
KR1020227013566A Withdrawn KR20220061249A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법
KR1020177024422A Ceased KR20170103039A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법
KR1020207019819A Ceased KR20200087870A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법
KR1020167002363A Withdrawn KR20160017123A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법
KR1020197001094A Ceased KR20190006612A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법

Family Applications After (7)

Application Number Title Priority Date Filing Date
KR1020077004461A Ceased KR20070049646A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물및 그의 제조방법
KR1020137009959A Expired - Fee Related KR101613775B1 (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법
KR1020227013566A Withdrawn KR20220061249A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법
KR1020177024422A Ceased KR20170103039A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법
KR1020207019819A Ceased KR20200087870A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법
KR1020167002363A Withdrawn KR20160017123A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법
KR1020197001094A Ceased KR20190006612A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법

Country Status (21)

Country Link
US (1) US20080050443A1 (https=)
EP (2) EP1786401B1 (https=)
JP (1) JP5147399B2 (https=)
KR (8) KR20160136465A (https=)
CN (1) CN101010068B (https=)
AR (1) AR050615A1 (https=)
AU (1) AU2005276583B2 (https=)
BR (1) BRPI0514682B8 (https=)
CA (1) CA2575499A1 (https=)
DK (1) DK1786401T3 (https=)
ES (1) ES2647671T3 (https=)
HU (1) HUE034653T2 (https=)
MX (1) MX2007002253A (https=)
MY (1) MY144297A (https=)
PE (1) PE20060652A1 (https=)
PL (1) PL1786401T3 (https=)
PT (1) PT1786401T (https=)
RU (1) RU2383332C2 (https=)
SI (1) SI1786401T1 (https=)
TW (1) TWI402082B (https=)
WO (1) WO2006021455A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1715893T3 (da) 2004-01-20 2009-11-09 Novartis Pharma Ag Direkte kompressionsformulering og fremgangsmåde
PL1712547T3 (pl) 2004-02-05 2012-04-30 Kyorin Seiyaku Kk Pochodna bicykloestrowa
AR050615A1 (es) 2004-08-27 2006-11-08 Novartis Ag Composiciones farmaceuticas para la administracion oral
EP1995237A4 (en) 2006-03-08 2011-07-06 Kyorin Seiyaku Kk PROCESS FOR PREPARING AN AMINOACETYLPYRROLIDINCARBONITRILE DERIVATIVE AND PRODUCTION PRODUCT THEREOF
WO2007128801A1 (en) * 2006-05-08 2007-11-15 Novartis Ag Combination of organic compounds
US8143427B2 (en) 2007-03-22 2012-03-27 Kyorin Pharmaceutical Co., Ltd. Method for producing aminoacetylpyrrolidinecarbonitrile derivative
DE102008020701A1 (de) * 2008-04-24 2009-10-29 Bayer Technology Services Gmbh Formulierung mit reduzierter Hygroskopizität
CA2732984A1 (en) 2008-08-07 2010-02-11 Kyorin Pharmaceutical Co., Ltd. Process for production of bicyclo[2.2.2]octylamine derivative
CN102186474A (zh) * 2008-08-14 2011-09-14 杏林制药株式会社 稳定的医药组合物
AR073651A1 (es) * 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
CN102438617A (zh) 2009-03-27 2012-05-02 杏林制药株式会社 含有碱性添加剂的基质型缓释制剂
JP2011057586A (ja) * 2009-09-08 2011-03-24 Kyorin Pharmaceutical Co Ltd ｐＨ非依存性マトリックス型徐放性製剤
TR201002256A1 (tr) * 2010-03-24 2011-10-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Stabil aliskiren formülasyonları
US9071358B2 (en) 2012-06-21 2015-06-30 Qualcomm Incrorporated Repeater fiber-coax units
US8989577B2 (en) 2012-06-21 2015-03-24 Qualcomm Incorporated Methods and systems for implementing time-division duplexing in the physical layer
US9363017B2 (en) 2012-07-06 2016-06-07 Qualcomm Incorporated Methods and systems of specifying coaxial resource allocation across a MAC/PHY interface
JP6283316B2 (ja) * 2012-10-26 2018-02-21 株式会社三和化学研究所 アナグリプチン含有固形製剤
WO2014152207A1 (en) * 2013-03-15 2014-09-25 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
CN104274408A (zh) * 2013-07-10 2015-01-14 北京科信必成医药科技发展有限公司 一种熔融包衣的速释药物微粒及其制备方法
US20150366813A1 (en) * 2014-06-20 2015-12-24 Banner Life Sciences Llc Liquid-filled immediate release soft gelatin capsules
WO2018050892A1 (en) 2016-09-16 2018-03-22 Galenicum Health S.L. Vildagliptin pharmaceutical compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109770A0 (en) * 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
WO1995005808A1 (en) * 1993-08-24 1995-03-02 Abbott Laboratories Oil-based tableting method
ATE212224T1 (de) * 1993-11-23 2002-02-15 Euro Celtique Sa Verfahren zur herstellung einer arzneizusammensetzung mit verzögerter wirkstoffabgabe
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US20020142037A1 (en) 1996-10-01 2002-10-03 Nabil Farah Process for the manufacture of a pharmaceutical composition with modified release of active principle comprising a matrix
WO1998018763A1 (en) 1996-10-25 1998-05-07 Tanabe Seiyaku Co., Ltd. Tetrahydroisoquinoline derivatives
US6011155A (en) 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
WO1999013864A2 (en) 1997-09-19 1999-03-25 Shire Laboratories, Inc. Solid solution beadlet
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6107317A (en) 1999-06-24 2000-08-22 Novartis Ag N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
CN1500080A (zh) 2001-02-02 2004-05-26 ����ҩƷ��ҵ��ʽ���� 稠合杂环化合物
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
WO2004024184A1 (ja) * 2002-09-11 2004-03-25 Takeda Pharmaceutical Company Limited 徐放性製剤
KR20050067418A (ko) 2002-10-18 2005-07-01 머크 앤드 캄파니 인코포레이티드 당뇨병을 치료 또는 예방하기 위한 베타-아미노헤테로사이클릭 디펩티딜 펩티다제 억제제
DE60332856D1 (de) 2002-10-23 2010-07-15 Bristol Myers Squibb Co Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
AR050615A1 (es) 2004-08-27 2006-11-08 Novartis Ag Composiciones farmaceuticas para la administracion oral

Also Published As

Publication number Publication date
KR20160017123A (ko) 2016-02-15
TWI402082B (zh) 2013-07-21
EP1786401B1 (en) 2017-08-16
ES2647671T3 (es) 2017-12-26
BRPI0514682A (pt) 2008-06-17
US20080050443A1 (en) 2008-02-28
PT1786401T (pt) 2017-11-22
MX2007002253A (es) 2007-04-20
TW200613005A (en) 2006-05-01
EP1786401A1 (en) 2007-05-23
CA2575499A1 (en) 2006-03-02
WO2006021455A1 (en) 2006-03-02
AU2005276583B2 (en) 2009-12-03
KR20190006612A (ko) 2019-01-18
KR101613775B1 (ko) 2016-04-19
JP5147399B2 (ja) 2013-02-20
DK1786401T3 (da) 2017-11-27
JP2008510764A (ja) 2008-04-10
KR20070049646A (ko) 2007-05-11
BRPI0514682B1 (pt) 2019-06-04
KR20130043697A (ko) 2013-04-30
KR20220061249A (ko) 2022-05-12
SI1786401T1 (sl) 2017-12-29
BRPI0514682B8 (pt) 2021-05-25
CN101010068B (zh) 2013-05-22
PL1786401T3 (pl) 2018-01-31
KR20170103039A (ko) 2017-09-12
HUE034653T2 (hu) 2018-02-28
PE20060652A1 (es) 2006-08-11
AU2005276583A1 (en) 2006-03-02
RU2007110953A (ru) 2008-10-10
MY144297A (en) 2011-08-29
KR20200087870A (ko) 2020-07-21
RU2383332C2 (ru) 2010-03-10
EP3087975A1 (en) 2016-11-02
CN101010068A (zh) 2007-08-01
AR050615A1 (es) 2006-11-08

Similar Documents

Publication Publication Date Title
KR101613775B1 (ko) 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법
JP7565589B2 (ja) グルコキナーゼ活性化剤およびｄｐｐ－ｉｖ阻害薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用
EP1441713B1 (en) Modified release tamsulosin tablets
ES2452019T3 (es) Comprimido bicapa que comprende telmisartán y amlodipino
CA2688721A1 (en) Stable pharmaceutical formulation for a dpp-iv inhibitor
EP4025192B1 (en) Process for producing a tablet comprising glp-1 peptides
CA2801020A1 (en) A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
RS53087B (sr) Čvrste farmaceutske kompozicije stalnog sastava koje sadrže irbesartan i amlodipin, njihovo dobijanje i terapijska primena
HK1205683A1 (en) Pharmaceutical formulation having improved stability
EP2468267B1 (en) Bilayer Combination Composition of Vildagliptin and Gliclazide
HK1227314A1 (en) Treatment with vildagliptin
WO2005092319A1 (en) Rapidly disintegrating pharmaceutical compositions comprising nateglinide and a disintegrant
WO2009105049A1 (en) Oral tablet compositions containing nateglinide and surfactan ph adjusting agent
CA2615319A1 (en) Compositions for oral administration of sustained release glutathione, methods for their production and uses thereof
EP1904071A2 (en) Compositions of antiviral compound

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20161118

Application number text: 1020167002363

Filing date: 20160127

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20161216

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170228

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170830

Application number text: 1020167002363

Filing date: 20160127

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20170831

WITB Written withdrawal of application